Fecal Calprotectin in Patients Infected with Intestinal Protozoan Infections
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Fecal Calprotectin in Intestinal Protozoa. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Calprotectin extracted from stool can be detected easily using ELISA. Numerous studies have shown that fecal calprotectin concentrations demonstrate a good correlation with intestinal inflammation This study aims to detect the relationship between fecal calprotectin and Blastocystis hominis and Entamoeba histolytica infections.
Primary outcome measures
- Prevalence of Blastocystis and Entamoeba [Time frame: 2 months]
Secondary outcome measures (1)
- Number of persons have high fecal calprotectin [Time frame: 6 months]
Eligibility criteria
Inclusion criteria
120 fecal samples will be collected as the following:
- 40 samples from patients complaining of gastrointestinal manifestations and only infected with B.hominis and E.histolytica.
- 40 samples from patients complaining of gastrointestinal manifestations without any protozoal infection.
- 40 healthy control cross-matched volunteers (without gastrointestinal manifestations, or intestinal parasites).
Exclusion criteria
- persons received antiparasitic drugs or antibiotic 2 weeks before sample collection Patients with mixed intestinal protozoa Patients with intestinal protozoa rather than Entamoeba histolytica and Blastocystis
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
Egypt · 1 center
- Sohag University — Sohag
Identifiers
NCT: NCT06890455 · Soh-Med--25-3-07MS